While many people wonder when will the Ozempic lawsuit be settled, litigation remains in the early stages
Thus, CMAP amplitude is dependent upon the number of axons, fidelity of neuromuscular transmission, and number/size of muscle fibres
Sigma-Tau Pharmaceuticals
(2008, Neurology) tested SubQ native rhIGF-1 in adult ALS patients
While long-term data on stopping and switching are still emerging, oral options provide an evidence-backed alternative for people who prefer not to use injectables

2 DOSAGE AND ADMINISTRATION DOSAGE & ADMINISTRATION SECTION 3 DOSAGE FORMS AND STRENGTHS DOSAGE FORMS & STRENGTHS SECTION Injection: clear, colorless solution available as follows: Single-Dose Pens Dose per Injection Total Strength per Total Volume 0.25 mg 0.25 mg/0.5 mL 0.5 mg 0.5 mg/0.5 mL 1 mg 1 mg/0.5 mL 1.7 mg 1.7 mg/0.75 mL 2.4 mg 2.4 mg/0.75 mL 7.2 mg (WEGOVY HD) 7.2 mg/0.75 mL Single-Patient-Use Pen (4 doses per Pen) (WEGOVY FlexTouch) Dose per Injection Total Strength per Total Volume 2.4 mg 9.6 mg/3 mL (3.2 mg/mL) Single-Dose Syringes Dose per Injection Total Strength per Total Volume 0.25 mg 0.25 mg/0.5 mL 0.5 mg 0.5 mg/0.5 mL 1 mg 1 mg/0.5 mL 1.7 mg 1.7 mg/0.75 mL 2.4 mg 2.4 mg/0.75 mL Tablets: available as: Tablet Strength Description 1.5 mg White to light yellow, round shaped debossed with 1.5 on one side and novo on the other side 4 mg White to light yellow, round shaped debossed with 4 on one side and novo on the other side 9 mg White to light yellow, round shaped debossed with 9 on one side and novo on the other side 25 mg White to light yellow, oval shaped debossed with 25 on one side and novo on the other side 4 CONTRAINDICATIONS CONTRAINDICATIONS SECTION WEGOVY is contraindicated in the following conditions: a personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )]
